Sun Pharma signs Definitive Agreement to Acquire Organon Sun Pharmaceutical Industries Limited and Organon & Co. have finalized a deal under which Sun Pharma will acquire all outstanding shares of Organon for US$14.00 per share in an all-cash transaction. The enterprise value of the deal is set at US$11.75 billion, marking a significant expansion for both companies. The acquisition, expected to close in early 2027, is subject to regulatory approvals and Organon stockholder approval. Organon, a global healthcare company spun off from Merck in 2021, specializes in women’s health and general medicines, with a portfolio of over 70 products. Its operations span 140 countries, including major markets such as the U.S., Europe, China, Canada, and Brazil. The company maintains six manufacturing facilities across the European Union and emerging markets, supporting its global footprint. Organon’s revenue for the year ended December 31, 2025, totaled US$6.2 billion, with Adjusted EBITDA of US$1.9 billion. It also reported debt of US$8.6 billion and a cash balance of US$574 million, bolstered by a recent divestiture that generated US$440 million in upfront payments. The acquisition aligns with Sun Pharma’s strategy to strengthen its Innovative Medicines business and expand its presence in biosimilars. The combined entity will become a top-25 global pharmaceutical company with projected revenue of US$12.4 billion, positioning it as a leader in Established Brands/Branded Generics and a top-3 player in women’s health. Sun Pharma’s entry into biosimilars as a Top-10 global player is a key outcome, leveraging Organon’s expertise and market reach. The deal also aims to enhance long-term value creation through synergies, including revenue upside opportunities and improved cash flow.#sun_pharma #merck #organon_co #organon #sun_pharmaceutical_industries_limited
